OKYO Pharma Ltd. — Form 6-K Summary
Reporting date: October 6, 2026. This Form 6-K reports that OKYO Pharma issued an announcement about its urcosimod clinical program. The company is a foreign private issuer that files annual reports on Form 20-F.
Business and clinical update
The company announced that the first patients have been enrolled in the Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain (NCP). The announcement is identified as Exhibit 99.1, but its text is not included in the supplied filing content.
Financial results and period comparisons
The supplied filing text provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics, and no prior-period comparison.
Outlook, risks, and other matters
No guidance, detailed management commentary, trial design or enrollment targets, expected timelines, risks, contingencies, or unusual financial items are provided in the supplied text.
The 6-K states that Exhibit 99.1 is furnished, not deemed filed for purposes of Exchange Act Section 18, and that the report is incorporated by reference into the company’s Form F-3 registration statement (Reg. No. 333-293145).
Key facts for investors to verify
- Review Exhibit 99.1 for the full announcement and any further details on the NEPTUNE trial.
- Verify the trial’s design, enrollment plans, milestones, and anticipated timing from the complete announcement or other company disclosures.
- Consult the company’s financial filings for current financial condition and liquidity; this 6-K excerpt contains no financial results.